Why Haemonetics Corporation’s (HAE) Stock Is Up 14.11%
As of Tuesday, August 18, Haemonetics Corporation’s HAE share price has surged by 14.11%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Omar Beirat
Michael Rose
Jenna Brashear
Jenna Brashear
| Share Statistics | HAE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,923.7 | $407.7 | 67% |
|
| Shares Out (Mil) | 45.7 | 41.3 | 45% |
|
| Institutional Ownership | 98.7% | 81.4% | 81% |
|
| Float (Mil) | 44.9 | 34.9 | 45% |
|
| Beta | 0.52 | 0.88 | 30% |
|
| Avg Daily Volume (000s) | 927 | 412 | 69% |
|
| Price Change (52-week) |
99.3% | 64.8% | 90% |
|
| Growth | HAE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.9% | 11.8% | 54% |
|
| Net Income (5yr) | 4.1% | (6.0%) | 46% |
|
| EPS (5yr) | 5.8% | 10.4% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (26.2%) | (16.2%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | $1.290 | $5.297 | $5.740 | |
| Month Ago EPS | $1.274 | $5.217 | $5.626 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $1.276 | $5.221 | $5.767 | |
| Year/Year Chg | 79.2% | 158.4% | 210.4% | |
| Financials | HAE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,352 | $119 | 55% |
|
| Net Income (TTM) (Mil) | $96 | ($9) | 60% |
|
| EPS (TTM) | $2.071 | ($0.400) | 72% |
|
| Operating Cash Flow (TTM) (Mil) | $328 | ($3) | 65% |
|
| Net Cash Flow (TTM) (Mil) | ($70) | $1 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $1,169 | $21 | 68% |
|
| Enterprise Value (Q1) (Mil) | $5,711 | $427 | 65% |
|
| Valuation | HAE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.88 | 3.06 | 81% |
|
| P/E | 52.6 | 27.8 | 85% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 9.1 | 1.7 | 93% |
|
| Ratios | HAE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.3% | 58.9% | 72% |
|
| Net Margin | 7.1% | (6.9%) | 55% |
|
| ROA | 4.0% | (12.7%) | 67% |
|
| ROE | 11.2% | (13.1%) | 61% |
|
| Liabilities to Assets | 64.6% | 46.0% | 59% |
|
| F-Score | 7 | 4 | 82% |
|
Haemonetics Corporation did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors